A Phase I/II Open-Label Dose Escalation Trial of CPI-613 in Combination With Docetaxel Chemotherapy as a Second-Line Treatment of Non-Small-Cell Lung Cancer
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 11 Jul 2018
Price : $35 *
At a glance
- Drugs CPI 613 (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 25 May 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as sponsor decided not to move forward
- 26 Apr 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jun 2018.
- 29 Mar 2018 Planned initiation date changed from 1 Mar 2018 to 1 Apr 2018.